CliffBio
biologic

Pneumovax 23

Pneumococcal Vaccine, Polyvalent

Loss of exclusivityNovember 1989projected — 12-year biologic exclusivity estimate
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand namePneumovax 23
Active ingredientPneumococcal Vaccine, Polyvalent
Strength25UG/.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalNovember 1977
Marketing statusRx

More from Merck Sharp & Dohme LLC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Pneumovax 23 patent cliff — loss of exclusivity November 1989 | CliffBio